Involvement of Merkel cell polyomavirus in the etiology and pathogenesis of Merkel cell carcinoma: A systematic review

Fernando Seiji Morais, Caio Santos Bonilha, Emerson Carraro

Pharmacy Department, Masters Program in Pharmaceutical Sciences, Universidade Estadual do Centro-Oeste (State University of Center-West) (UNICENTRO), Guarapuava-PR, Brazil

Email address: fernandoseiji.morais@yahoo.com.br (F. S. Morais), caiosantosb@hotmail.com (C. S. Bonilha), emersoncarraro@bol.com.br (E. Carraro)


Abstract: Merkel Cell Polyomavirus (MCV) is a virus belonging to the human Polyomavirus family. After its discovery and detection in approximately 80% of Merkel Cell Carcinoma (MCC) tumors, it has been associated with this rare and aggressive skin cancer that primarily affects elderly and immunosuppressed people. In this study, a systematic review was developed to gather and evidence information about the involvement of MCV infection in the development of MCC. An analysis was performed in the PubMed database in order to find articles to answer the purpose of the present study. Ninety-seven articles met the criteria, forty-six of them investigated the prevalence of MCV in MCC clinical samples, and all showed that the MCV-MCC association exists, with the viral presence ranging from 18 to 100% in MCC tumors. In addition, results pointing to the MCV potential carcinogenic, infection, transmission and replication mechanisms, or even possible disease markers or therapeutic evaluations were found. Current literature has demonstrated frequent involvement of MCV in MCC, with survey of some disease indicative laboratory markers and possible therapeutic evaluations.

Keywords: Merkel Cell Carcinoma, Merkel Cell Polyomavirus, Carcinogenesis

1. Introduction

The transformation process of normal cells into malignant tumor cells is caused by sequence genetic mutations and consists of sequential stages in cascade [1]. The genome sequencing efforts have identified a large number of somatic genomic alterations and numerous germinal mutations associated with cancer predisposition. Viruses inherently depend on the host cell and during the course of infection may result in pathological phenotypes similar to those observed in mutations that lead to carcinogenesis [2].

Some associations between viruses and cancer in humans are described in the literature. Among the most common, one can cite the connection between the Epstein-Barr virus (EBV) and gastric tract cancers, Burkitt’s lymphoma and nasopharyngeal carcinomas [3]; hepatitis C virus (HCV) and the hepatocellular carcinoma [4]; and human papillomavirus (HVP) and cervical, anal, vaginal, vulvar and penile cancers [5].

Merkel Cell Polyomavirus (MCV) belongs to the family of human Polyomaviruses. This family consists of 10 members, being so far the MCV the only associated with cancer development, specifically Merkel Cell Carcinoma (MCC) [6]. MCV is a small, non-enveloped and double-stranded DNA virus [7], unknown until mid-2008 when its DNA was found in tumors of MCC. Thenceforth, the MCV has been reported in approximately 80% of cases of individuals with MCC [8].

MCC is a rare type of skin cancer of neuroendocrine origin [6] and was first described in 1972 by Toker [9]. This potentially fatal cancer consists of a malignant tumor that affects mostly white elderly people and immunocompromised individuals, such as transplant or AIDS patients. Other possible risk factors for the development of this cancer are histories of non-melanoma skin cancer, leukemia or lymphoma [10, 11]. The incidence of MCC increased sharply between mid-70’s and 2006, tripling over this period (from 0.2 to 0.6/100,000 cases per population in the US) [12], with a mortality rate estimated of one-third of diagnosed patients [13].

Likely due to its association with MCC, MCV has gained attention in the clinical and scientific community, as it helps to understand the etiologic context of this disease [10]. In this work, a systematic review was developed to gather information and evidence about the involvement of MCV infection in the development of the MCC.
2. Methods

A systematic review in PubMed database was performed using the keywords "Merkel cell carcinoma" and "Merkel cell polyomavirus," in search of original papers focusing on the MCV-MCC association published between February 2008 and September 2014 and with available summary. The literature survey was done in the months from May to October 2014.

The studies were selected through the title, summaries and further reading of the full work. Clinical trials, case reports, in vitro assays and research and support works were analyzed. Ninety-seven studies that met the inclusion criteria for this study were selected.

3. Results and Discussion

3.1. Results

The 97 studies selected for review were analyzed. Among the studies investigating the prevalence of MCV in MCC clinical samples (46 studies), all detected the virus in at least a portion of the analyzed samples, with relatively high but variable prevalence (ranging from 18 to 100%). And thus, confirming the MCV-MCC association. The results found in the works include the possible carcinogenic and infection mechanisms of MCV, replication and transmission, and possible disease markers or therapeutic evaluation.

3.2. MCV and MCC Association

In USA, Feng and coworkers (2008) reported the presence of MCV genomic sequence in approximately 80% of MCC tissues analyzed by using the polymerase chain reaction (PCR). In addition to these findings, clonal integration of the virus into the genome of tumors was confirmed by using digital transcriptome subtraction (DTS) [14]. From this study, it was suggested that MCV infection and the integration of viral DNA in the tumor cells prior to clonal expansion of tumor cells [14 - 16]. Forty-five subsequent studies conducted in various locations and using different methods for detection of MCV also showed high prevalence of MCV in MCC tumors. A few studies have reported a lower prevalence [17 - 19], although the integrity of the sample may have influenced the results, as well as the collection epoch, whereas samples collected at an interval of 10 years showed high divergence of positivity for MCV [17]. However, the MCV was proposed as a possible specific marker for differentiation of MCC from other histologically similar cutaneous malignancies [20 - 23]. Epidemiological studies of MCV in patients with MCC are summarized in Table 1.

With the high detection rate of MCV in these tumors, it was suggested that the improvement of the detection methods would increase the frequency of MCV found in MCC tumors [24 - 27]. A greater prevalence of MCV in MCC tumors using an immunohistochemical (IHC) method with Ab3 (anti-anti-idiotype antibodies), a new mouse monoclonal antibody against MCV LT (large T) antigen, compared with those obtained by the use of CM2B4, a monoclonal antibody that was traditionally used for the detection of MCV LT, were reported. Furthermore, the expansion of the MCV repertoire of primers for PCR, showed results of 100% positivity for MCV DNA in MCC samples [25, 28]. Detection of MCV with antibodies against the T antigens can also be used for both monitoring of therapy to assess regression, as for evaluating the stage of the disease and recurrence [29, 30]. In a prospective study, the presence of T antigens or neutralizing antibodies against MCV was indicated as a risk factor for development of the MCC [31].

Cytokeratin-20 (CK20) is a common marker for the identification of MCC, but despite the simultaneous presence of CK20 with seropositivity to antibodies against the MCV small T (sT) antigen was observed in MCC tumors [29], the marker should not be used to identifying viral presence in the tumor [32, 33]. Although the MCV DNA was found in tissues from lymphoid cancers, the MCV LT antigen was not detected in tumor cells by these malignancies using monoclonal antibodies against the LT, suggesting a non-viral causation these cases [34].

The MCV DNA can be detected in healthy individuals or non-MCC patients, showing a possible contact with the virus in the general population at some stage of life, and that the infection may be asymptomatic in most individuals [35 - 37]. However, immunosuppression of the individual is the primary risk factor for cancers of viral etiology [38]. Thus, the disease state (e.g., AIDS), advanced age, or chemotherapy treatment for other malignancies can lead to a high rate of virus replication, triggering the possible carcinogenic mechanism [11, 39, 40]. When detected in MCC tissues, the viral load of MCV are vastly greater than those observed in non-cancerous tissues [30, 41], occurring viral mutations which appear to be specific signatures for carcinogenesis [24]. There is no apparent correlation between age or sex of individuals and the infection by MCV, however, for MCC cases, a slight tendency in females was observed [42]. Although it is most common in the skin, the MCC can metastasize [43 - 46] or become recurrent, while this makes it difficult to differentiate these two events [47].

There is a correlation between the MCC and other malignancies, especially in the skin [42], highlighting the squamous cell carcinoma (SCC) [48, 49], basal cell carcinoma (BCC) [48, 50], and chronic lymphocytic leukemia (CLL) [51], which lead to risk of developing MCC as a secondary cancer, and vice-versa. There are other types of cancers associated with MCC, although with less number of records, making it difficult to consolidate data [52 - 55]. Despite the association between MCC and other cancers, apparently there is no involvement of the MCC and these other malignancies [50, 53, 56 - 59]. There are a few exceptions that show association between MCC and other cancers: the presence of MCV in Kaposi's sarcoma [54] and the detection of MCV in SCC tumors, with concomitant presence of human papillomavirus (HPV) in a combined tumor of MCC and SCC, suggesting a possible synergism of oncovirus [60].

The transmission route of MCV is not yet established. Another study reported a mechanism of fecal-oral...
transmission as plausible after having been detected high levels of MCV in samples of digestive tract compared to samples of skin, respiratory tract, saliva and from the liver. Samples analyzed by the group for this purpose were from non-MCC tissues [41]. Although the MCV has been detected in samples of placenta, there is no evidence of maternal-fetal transmission [61].

### Table 1. Forty-six studies that show MCV-MCC association

<table>
<thead>
<tr>
<th>Author/year</th>
<th>Local of study</th>
<th>Method</th>
<th>MCV positivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feng/2008 [14]</td>
<td>USA</td>
<td>PCR</td>
<td>80% (8/10)</td>
</tr>
<tr>
<td>Kuwarnamotor/2011 [15]</td>
<td>Japan</td>
<td>PCR, IHC (CM2B4)*</td>
<td>77% (20/26), 81% (21/26)</td>
</tr>
<tr>
<td>Sastre-Gara/2011 [16]</td>
<td>France</td>
<td>PCR</td>
<td>100% (10/10)</td>
</tr>
<tr>
<td>Gavrskii/2011 [17]</td>
<td>USA, Australia</td>
<td>PCR</td>
<td>69% (11/16), 24% (5/21)</td>
</tr>
<tr>
<td>Paik/2011 [18]</td>
<td>Australia</td>
<td>IHC (CM2B4)</td>
<td>18% (19/104)</td>
</tr>
<tr>
<td>Duncavage/2009 [20]</td>
<td>USA</td>
<td>PCR</td>
<td>78% (32/41)</td>
</tr>
<tr>
<td>Erovi/2013 [23]</td>
<td>Canada</td>
<td>IHC (CM2B4)</td>
<td>97% (29/30)</td>
</tr>
<tr>
<td>Laude/2010 [24]</td>
<td>France</td>
<td>PCR</td>
<td>95% (41/43)</td>
</tr>
<tr>
<td>Ota/2012 [25]</td>
<td>Japan</td>
<td>PCR, IHC (CM2B4)</td>
<td>100% (9/9), 89% (8/9)</td>
</tr>
<tr>
<td>Hattoni/2013 [26]</td>
<td>Japan</td>
<td>PCR, IHC (CM2B4)</td>
<td>88% (23/26), 77% (20/26)</td>
</tr>
<tr>
<td>Carter/2009 [27]</td>
<td>USA</td>
<td>PCR, ABA (VP1a)</td>
<td>77% (24/31), 94% (29/31)</td>
</tr>
<tr>
<td>Rodig/2012 [28]</td>
<td>USA</td>
<td>PCR, IHC (Ab3), IHC (CM2B4)</td>
<td>100% (60/60), 97% (56/58), 81% (46/57)</td>
</tr>
<tr>
<td>Paulson/2010 [29]</td>
<td>USA</td>
<td>IHC (CM2B4)</td>
<td>77% (108/139)</td>
</tr>
<tr>
<td>Touzé/2011 [30]</td>
<td>France</td>
<td>PCR, ELISA</td>
<td>75% (51/68), 65% (44/68)</td>
</tr>
<tr>
<td>Faust/2013 [31]</td>
<td>Sweden, Norway</td>
<td>IHC</td>
<td>86% (19/22), 50% (11/22)</td>
</tr>
<tr>
<td>Andres/2010 [32]</td>
<td>Germany</td>
<td>PCR</td>
<td>64% (21/33)</td>
</tr>
<tr>
<td>Shuda/2009 [34]</td>
<td>Spain</td>
<td>IHC (CM2B4)</td>
<td>58% (21/36)</td>
</tr>
<tr>
<td>Foulonne/2010 [35]</td>
<td>France</td>
<td>PCR</td>
<td>78% (14/18)</td>
</tr>
<tr>
<td>Wieland/2009 [36]</td>
<td>Germany</td>
<td>PCR</td>
<td>88% (30/34)</td>
</tr>
<tr>
<td>Loyoy/2010 [41]</td>
<td>USA</td>
<td>PCR</td>
<td>86% (67/77)</td>
</tr>
<tr>
<td>Bhatia/2010 [43]</td>
<td>USA</td>
<td>PCR</td>
<td>74% (17/23)</td>
</tr>
<tr>
<td>Wetzel/2009 [45]</td>
<td>Netherlands</td>
<td>PCR</td>
<td>40% (2/5)</td>
</tr>
<tr>
<td>De Biase/2012 [46]</td>
<td>Italy</td>
<td>PCR</td>
<td>100% (18/18)</td>
</tr>
<tr>
<td>Reisinger/2010 [49]</td>
<td>USA</td>
<td>IHC (CM2B4)</td>
<td>75% (15/20)</td>
</tr>
<tr>
<td>Katano/2009 [54]</td>
<td>Japan</td>
<td>PCR</td>
<td>55% (6/11)</td>
</tr>
<tr>
<td>Ly/2012 [55]</td>
<td>Canada</td>
<td>IHC (CM2B4)</td>
<td>63% (17/27)</td>
</tr>
<tr>
<td>Busam/2009 [57]</td>
<td>USA</td>
<td>PCR, IHC (CM2B4)</td>
<td>88% (15/17), 67% (11/17)</td>
</tr>
<tr>
<td>Jung/2011 [58]</td>
<td>Korea</td>
<td>PCR, IHC (CM2B4)</td>
<td>86% (12/14), 85% (11/13)</td>
</tr>
<tr>
<td>Mangana/2010 [59]</td>
<td>Switzerland</td>
<td>PCR</td>
<td>67% (20/30)</td>
</tr>
<tr>
<td>Sihto/2009 [63]</td>
<td>Finland</td>
<td>PCR</td>
<td>80% (91/114)</td>
</tr>
<tr>
<td>Martel-Jantin/2012 [70]</td>
<td>France</td>
<td>PCR</td>
<td>61% (59/97)</td>
</tr>
<tr>
<td>Nakamura/2010 [71]</td>
<td>Japan</td>
<td>PCR, IHC (LT252)</td>
<td>58% (11/19), 39% (7/18)</td>
</tr>
<tr>
<td>Kassem/2008 [73]</td>
<td>Germany</td>
<td>PCR</td>
<td>77% (30/39)</td>
</tr>
<tr>
<td>Handshel/2010 [80]</td>
<td>Germany</td>
<td>PCR</td>
<td>66% (29/44)</td>
</tr>
<tr>
<td>Schrama/2011 [81]</td>
<td>Germany, Australia</td>
<td>PCR</td>
<td>85% (116/136), 87% (33/38)</td>
</tr>
<tr>
<td>Iwasaki/2013 [83]</td>
<td>Japan</td>
<td>PCR, IHC (CM2B4)</td>
<td>74% (32/43), 68% (29/43)</td>
</tr>
<tr>
<td>Houben/2010 [87]</td>
<td>USA</td>
<td>USA</td>
<td>78% (43/50)</td>
</tr>
<tr>
<td>Hall/2012 [90]</td>
<td>USA</td>
<td>IHC (CM2B4)</td>
<td>47% (17/36)</td>
</tr>
<tr>
<td>Waltari/2011 [91]</td>
<td>Finland</td>
<td>PCR</td>
<td>77% (67/87)</td>
</tr>
<tr>
<td>Nakajima/2009 [95]</td>
<td>Japan</td>
<td>PCR</td>
<td>79% (11/14)</td>
</tr>
<tr>
<td>Matsuishi/2014 [100]</td>
<td>Japan/UK</td>
<td>PCR, ISH, IHC (CM2B4)</td>
<td>50% (16/32), 50% (16/32), 50% (16/32)</td>
</tr>
<tr>
<td>Xie/2014 [101]</td>
<td>Sweden</td>
<td>PCR, IHC (CM2B4), IHC (Ab3)</td>
<td>42% (14/33), 36% (12/33), 85% (28/33)</td>
</tr>
<tr>
<td>Becker/2009 [106]</td>
<td>Germany</td>
<td>PCR</td>
<td>85% (45/53)</td>
</tr>
<tr>
<td>Varga/2009 [107]</td>
<td>Hungary</td>
<td>PCR</td>
<td>78% (79)</td>
</tr>
<tr>
<td>Paulini/2011 [108]</td>
<td>Italy</td>
<td>PCR</td>
<td>89% (89)</td>
</tr>
<tr>
<td>Perez-Ramirez/2008 [109]</td>
<td>France</td>
<td>PCR</td>
<td>89% (89)</td>
</tr>
</tbody>
</table>

ISH: in situ hybridization; ABA: antibody-binding assay; CM2B4: monoclonal antibody against MCV LT antigen; VP1a: monoclonal antibody against MCV capsid protein VP1; Ab3: monoclonal antibody against MCV LT antigen; LT252: monoclonal antibody against MCV LT antigen.

The classification of MCC cell lines is made under the name of "classical" and "variant" phenotypes. These phenotypes are further divided into subtypes based on morphology and expression of genes taken neuroendocrine markers [62]. It has been suggested that the classical phenotype is for the MCC MCV-positive strains, and the MCC-negative strains are the variant [43]. However, Fischer et al. (2010) suggested a new classification based on the presence of virus integration patterns and mutations in LT protein. This new classification was proposed after both MCV-positive and negative MCC cell lines with features belonging to the classical variety were discovered [62]. MCC cases may have the expression of retinoblastoma protein (pRb) or not. The subgroups expressing pRb carry high levels of viral load of the MCV and also express LT antigen. MCCs with low level or no expression of pRb and LT antigen carry low or undetectable viral load, and in these groups the survival rate tends to be lower [43].
A persuasive fact that supports the hypothesis that MCV is an etiological factor for MCC is the clonal integration of the virus into the tumor cells genome. The virus appears to be integrated in head-tail manner as concatemers, randomly distributed in different locations throughout the cell genome [14]. T antigen proteins have been frequently observed in MCC tumors, the majority of these are positive for presence of MCV LT antigen and only tumor cells are reactive for antibodies against LT antigen [63]. Many MCV-positive tumors that are not reactive to LT express reactivity with specific antibodies against sT antigen of the virus. Recently, it has been suggested that sT antigen is most commonly expressed in MCC tumors than LT [34]. Clinical studies showed that metastasis rate of MCV-positive tumors is less frequent than in MCV-negative cancers. Thus, although the prevalence of MCV genome in MCC tumors is high, patients with the MCV-positive have a better prognosis [30, 32, 63].

### 3.3. Possible Carcinogenic Mechanisms of MCV

Sequencing of the MCV complete genome revealed characteristics of a polyomavirus, including a 5387 base pairs circular double stranded DNA, a primary region that encodes genes for small and large T antigens, a late region with genes for the viral capsid proteins VP1, VP2 and VP3, and a regulatory region that contains the viral origin of replication and bidirectional promoters for the primary and late genes [28]. It is known that the capsid protein VP1 interacts with N-acetylneuraminic acid of gangliosides that are important for viral entry and integration of the plasmid into the host cell [64]. The MCV LT modulates helicase activity, which plays a key role in viral replication by binding the origin of replication and triggering [65]. There are many plausible mechanisms by which the MCV induces cell transformation. The most knowable path involves constitutive expression of LT and sT proteins, with the hypothesis that MCV LT is the primary oncoprotein and sT exerts an accessory role in carcinogenesis [66 - 68].

Figure 1 outlines the possible carcinogenic mechanisms triggered by MCV proposed by the studies reviewed.

![Figure 1. Schematization of possible carcinogenic mechanisms of MCV.](image)

Studies on the role of mutations in MCV T antigen after clonal integration of the virus into host cells and its implication in the development of MCC report truncated deletions or mutations in exon 2, which encodes LT helicase [49, 69 - 71]. Mutations in exon 3 were also reported, leading to the loss of C-terminal region of the MCV. This region interacts with p53, increasing its phosphorylation and activation, thus its loss seems to lead to a stimulation of cell...
growth, favoring the tumors development [68, 72]. In addition to this, a deletion in VP1 has been identified in various MCV strains detected in MCC tumors. This deletion in other Polyomavirus is correlated to integration of clonal virus into the host genome or as a consequence of the event [73].

There are some possible explanations for the fact that solar exposure is a likely risk factor for the development of MCC. The mutant LT antigen found in MCC inhibits the repair that ultraviolet radiation (UVR) typically causes on DNA, probably mediated by decreasing expression of the XPC protein, which recognizes the DNA damage and initiate the repair process, and may be involved in carcinogenesis [66]. Furthermore, UVR can increase the expression levels of messenger RNA (mRNA) of MCV sT antigen [74]. The presence of high rates of pyrimidine dimers substitutions between mutations at the LT was observed, suggesting a of UVR role in transformation process [69]. The lowest prevalence of MCV in MCC tumors reported in some studies in Australia [17, 18] suggests that the viral cause is not major for development of MCC in this region. The highest rate of sun exposure and clearer skin can be a risk factor for this population [18].

It is suggested that LT protein derivative from MCC tissues acquire mutations that leads to complete replication ablation of MCV, and that these truncated mutations at the LT, as well as the loss of viral replication are essential events for the tumorigenesis induction by MCV [24, 68, 69]. Moreover, it has been proposed that the LT N-terminal half-chain need to be intact so the LT can bind to Brd4 (bromodomain-containing protein 4). This connection plays a critical role in DNA transcription, cellular growth and replication of MCV in host cells [75]. Other studies show that despite changes in the helicase activity and loss of viral replication, the mutations did not affect the binding portion of the LT with pRb [76, 77]. Recently, it was found that the DNA damage response (DDR) of the host is important for replication of MCV after undergoing mutations that lose normal replication mechanism. It was seen that the DDR inhibition affects the mutant LT replication in vitro [78]. Another observed consequence of changes in LT was that it inhibits the expression of the toll-like 9 receptor (TLR9) mRNA, interfering with the host immune system activity [79].

Some authors have reported that even with possible viral causation, there is no correlation between the presence of the MCV and the disease course in MCC [80, 81]. However, there is evidence that the two types of MCC tumors develop through different pathways [15, 43, 82]. The morphology of MCV-positive tumors is typical, while the MCV-negative exhibit highly variable morphology [15, 83]. There are reports of a strong association between pRb and expression and presence of LT antigen in MCC tumors, suggesting that MCV LT antigen has an essential role in oncogenesis of MCV-positive MCC. LT binds to pRb and prevents the formation of RB-E2F complex, allowing cell progression [68, 84 - 87]. In MCV-negative MCC, it is observed a decrease in pRb expression, an important factor for tumorigenesis in these cases [88]. There are also indications that mutations in the p53 family occurs only in cases of MCV-negative cancers. These clues suggest that the involvement of p53 in tumor genesis of the MCC is not related to infection by MCV. However, it is not possible to exclude the hypothesis that this infection cannot be involved at some stage of tumor evolution with changes in the p53 activity [67, 77, 86, 89 - 93].

The notion that the LT antigen expression is necessary for the maintenance of MCV-positive tumor cell lines was put to the test by the use of doxycycline to induce small hairpin RNA (shRNA) for inhibition of the MCV T antigens. The silencing of expression of T antigen in samples from some MCV-positive MCC cell lines showed a clear reduction in cell viability within days [67, 94]. Moreover, good results have been reported with the use of interferons (INFs) for negative regulation of LT expression in MCV-positive tumor cell lines [67], and complete tumor regression in a case report [95]. Although, Houben et al. (2011) presented results that the MCC MCV-positive lineage Loke did not subside even with the silencing of viral T antigens. Thus, it was suggested that MCV operates only in the early carcinogenic process in some MCC cases, and that the loss of MCV after this step may take the cancer to a more aggressive behavior [76, 96].

The sT antigen of MCV also seems to play an important role in development of malignant tumors by disrupting the activity of PP2A proteins family, which oppose the activity of signaling kinases essential for the cell cycle progression [69]. The sT oncoprotein also promotes the phosphorylation of 4E-BP1, a negative regulator of protein translation that is normally phosphorylated by mTOR (mammalian target of rapamycin). The phosphorylation of 4E-BP1 by sT-mediated pathway increases its stationary period in relation to mTOR phosphorylation of the Akt-mTOR pathway, keeping it inactive for longer. In addition, sT antigen appears to enhance the expression of LT, and protects it from proteosomal degradation mediated by ubiquitination by Fbw7 tumor suppressor [97]. However, despite the sT antigen itself be able to inducing a cell transformation, the more likely it is that both MCV T antigens act in concert to cause cell transformation and trigger the proliferation of malignant cells [98, 99]. The detection of both T antigens may help in understanding the mechanisms that trigger carcinogenesis in each tumor [100].

Another reported factor that probably contributes to MCV-mediated oncosogenesis is the expression of an oncoprotein named survivin (BIRC5 - baculoviral inhibitor of apoptosis repeat-containing 5) seven fold in MCV-positive MCC tumors than in MCV-negative [88]. Since the expression of survivin is controlled by LT, which pRb binding domain needs to be intact for the oncoprotein gene transcription, LT antigen appears to be necessary for survival of MCV-positive tumors, and may be a therapeutic target [23, 88, 101]. It was also observed regression of tumors introduced by xenography in mice by inhibition of survivin [102]. The use of miR203 to silence the expression of survivin showed good results only in MCV-negative MCC strains [101]. Another signaling pathway, which often presents activated in human cancers is the PI3K/AKT. This protein was identified activated in cases of MCC with
mutations in some genes possibly involved in the process. However, activation of this pathway was not related to the presence of MCV in the tumors, so it appears to be independent of viral infection [103]. The observation of lymphocyte infiltration in MCC tumors indicates that T antigens are immunogenic, and the exact knowledge of the epitopes may help in vaccine development [39].

Some studies indicate that despite the high prevalence of MCV in MCC tumors, the MCV-negative tumors are faster growing and more aggressive, representing a worse prognosis [84, 104]. Akgül and colleagues study (2011) showed that MCV-positive cancers cell lines MKL-1, MS-1, WaGa and MKL-2, showed lower levels of β-5 integrin expression when compared to MCV-negative cell lines. β-5 integrin is a subunit of heterodimeric membrane receptors, important for adhesion to extracellular matrix (ECM). Therefore, these cell lines do not grow adhered to the ECM, but in suspension, with a slower proliferation than MCV-negative tumors [105].

4. Conclusions

High prevalence of MCV in MCC has been proven by several studies. An improvement in methods of detection may possibly show that this prevalence is still higher than what has been preconized. Although the exact mechanism by which the MCV leads to cell transformation is not fully elucidated, there is strong evidence of its carcinogenic potential with viral T antigens, and that the two tumor lineages develop by different pathways. These antigens play essential roles in the progress of MCV-positive MCC, and the LT antigen is primarily responsible for triggering the carcinogenic mechanism with sT antigen exerting an advisory role, both consisting in potential therapeutic targets. This systematic review points to the proof of evidence of the association of MCV in MCC tumor development, with high viral detection, integration of genome and detection of viral T antigens. Additionally, some risk factors were identified, such as solar exposure and immunosuppression, and the possibility of using some markers as indicative of disease and possible therapeutic evaluation.

References


